A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

This publication has 29 references indexed in Scilit:

• Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
  Clinical Cancer Research, 2011
• Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
  Acta Oncologica, 2009
• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
  Annals of Oncology, 2008
• Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
  Clinical Cancer Research, 2008
• Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor
  Clinical Cancer Research, 2008
• Dose Selection in Phase I Studies: Why We Should Always Go for the Top
  Journal of Clinical Oncology, 2008
• E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
  International Journal of Cancer, 2007
• Hypertension as a predictive factor of Sunitinib activity
  Annals of Oncology, 2007
• The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
  European Journal Of Cancer, 2006
• Comparison of four basic models of indirect pharmacodynamic responses
  Journal of Pharmacokinetics and Biopharmaceutics, 1993